News

Date Title View
Toggle Summary Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Wednesday, February 28, 2018
DURHAM, N.C. --(BUSINESS WIRE)--Feb. 21, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), announced today that its fourth quarter and full year 2017 financial results will be released after the market closes on Wednesday, February 28, 2018 .
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of John LaRocca as General Counsel
DURHAM, N.C. --(BUSINESS WIRE)--Feb. 20, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Scott Cassady as Regional Sales Director for the Central Region
DURHAM, N.C. --(BUSINESS WIRE)--Feb. 12, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Brad Fuller as Director of National Accounts in its Market Access Department
IRVINE, Calif. --(BUSINESS WIRE)--Feb. 8, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Tad Heitmann as Head of Communications
IRVINE, Calif. --(BUSINESS WIRE)--Feb. 1, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Public Offering of Common Stock
IRVINE, Calif. --(BUSINESS WIRE)--Jan. 23, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma or ocular hypertension and other
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointments of Nils Hauptmann as Director of Regulatory Affairs and Pharmacovigilance and Tim Swan as Director of Sales and Transparency Operations
IRVINE, Calif. --(BUSINESS WIRE)--Jan. 16, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Julia Williams as Director of Medical Affairs
IRVINE, Calif. --(BUSINESS WIRE)--Jan. 2, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the
View HTML
Toggle Summary Rhopressa® (netarsudil ophthalmic solution) 0.02% Label
Toggle Summary Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa® (netarsudil ophthalmic solution) 0.02% for the Lowering of Elevated Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension
Product Approved Ahead of the Scheduled PDUFA Date of February 28, 2018 IRVINE, Calif. --(BUSINESS WIRE)--Dec. 18, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of
View HTML